EGI
AERI

EAM Global Investors’s Aerie Pharmaceuticals AERI Stock Holding History

EAM Global Investors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,821
Closed -$706K – 181
2017
Q4 		$706K Buy
+11,821
New +$717K 0.36% 124

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Global Investors's AERI Position: Q1 2018 in Review

EAM Global Investors sold out of Aerie Pharmaceuticals (AERI) in Q1 2018, closing a stake of 11,821 shares — an estimated $706K sold.

EAM Global Investors first reported a position in AERI in Q4 2017 and held it in 1 quarter. The position peaked at $706K in Q4 2017. 172 funds tracked by Wall St. Rank hold AERI as of Q1 2018.

  • EAM Global Investors reported no remaining Aerie Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • EAM Global Investors sold 11,821 Aerie Pharmaceuticals shares in Q1 2018, an estimated $706K.
  • EAM Global Investors first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • EAM Global Investors's Aerie Pharmaceuticals position peaked at $706K in Q4 2017.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2018.

Based on EAM Global Investors's 13F filing for Q1 2018, filed 4 Jun 2018.